Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes.
about
Comparable efficacy and safety of insulin glulisine and insulin lispro when given as part of a Basal-bolus insulin regimen in a 26-week trial in pediatric patients with type 1 diabetes.Efficacy and safety of switching to insulin glulisine from other rapid-acting insulin analogs in children with type 1 diabetes.Comparative pharmacodynamic and pharmacokinetic characteristics of subcutaneous insulin glulisine and insulin aspart prior to a standard meal in obese subjects with type 2 diabetes.Prevalence, Awareness, Treatment and Control of Diabetes Mellitus in a Chinese Population.Combining insulins for optimal blood glucose control in type I and 2 diabetes: focus on insulin glulisine.Insulin glulisine: efficacy and safety compared with other rapid-acting insulin analogues.Paediatric diabetes: achieving practical, effective insulin therapy in type 1 and type 2 diabetes.New developments in the treatment of type 1 diabetes in children.Effect of age of infusion site and type of rapid-acting analog on pharmacodynamic parameters of insulin boluses in youth with type 1 diabetes receiving insulin pump therapy.Insulin glulisine: an evaluation of its pharmacodynamic properties and clinical application.Pediatric Dosing and Body Size in Biotherapeutics.Treatment options for paediatric diabetes.The role of insulin glulisine to improve glycemic control in children with diabetes mellitus.Diversity in diabetes: the role of insulin aspart.Faster-acting insulin aspart provides faster onset and greater early exposure vs insulin aspart in children and adolescents with type 1 diabetes mellitus.20 Years of insulin lispro in pediatric type 1 diabetes: a review of available evidence.Prevalence, awareness, treatment and control of diabetes mellitus among middle-aged and elderly people in a rural Chinese population: A cross-sectional study.
P2860
Q34610273-F999DE19-E45C-4D4E-88FE-C1C34647908CQ34976700-FAD5CA26-14D9-49E3-B9A9-45730460D5FEQ35094152-861AB785-ED47-493E-9CC6-864D51BB4EF0Q35994764-B19E4969-EE60-4FAF-913A-6370BC5FB34EQ36541464-6EE9AC8B-8800-4031-A7C6-1F3E82110BEEQ36689044-FC1E1AD5-C47D-4E8E-BF82-68F648BBD589Q36971945-CE9FDDC1-46A0-4E2D-8762-A2E66942F0BCQ36978565-2A8815D0-5CBC-4E5E-9041-3E81517B3421Q37067084-18944262-3094-41C9-A9D3-FD7507043EA7Q37428378-017DAC3F-6393-4A17-B12E-2FB066036F4BQ37666711-1AA79EEF-307E-415D-913A-6A4C41477A28Q37776269-2ECE22FE-4127-4F0F-8484-0ED3FAD35C51Q37857690-BD83DEBF-9386-41A1-B226-3D1660461FBEQ37893108-73770BC3-983D-4003-A590-3CC3400869E8Q38381201-937EC2E5-E840-4551-8E2F-4AC71959DE8AQ38889745-71171B48-5B2F-4C19-A6F1-CC2175A05CF6Q55262838-79868381-E8CF-4E35-A9A1-B721B4560E80
P2860
Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Pharmacokinetics, prandial glu ...... lescents with type 1 diabetes.
@en
Pharmacokinetics, prandial glu ...... lescents with type 1 diabetes.
@nl
type
label
Pharmacokinetics, prandial glu ...... lescents with type 1 diabetes.
@en
Pharmacokinetics, prandial glu ...... lescents with type 1 diabetes.
@nl
prefLabel
Pharmacokinetics, prandial glu ...... lescents with type 1 diabetes.
@en
Pharmacokinetics, prandial glu ...... lescents with type 1 diabetes.
@nl
P2093
P921
P1433
P1476
Pharmacokinetics, prandial glu ...... lescents with type 1 diabetes.
@en
P2093
Annke D Frick
Claudia Bittner
Klaus Rave
Reinhard H A Becker
Thomas Danne
P304
P356
10.2337/DIACARE.28.9.2100
P407
P577
2005-09-01T00:00:00Z